Promising preclinical data generated from studies combining RTK and PI3K inhibitors indicate that antitumour responses to PI3K inhibition can be significantly enhanced in triple negative breast cancer models through the combination with a dual EGFR/HER3 antagonist in vitro and in vivo, with important implications for this relatively hard to treat subtype [64]. The gene discussed is PIK3CD; the disease is triple-negative breast carcinoma.